Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T62151
|
|||||
| Target Name |
Monoamine oxidase (MAO)
|
|||||
| Synonyms |
Human monoamine oxidase
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 5 Target-related Diseases | + | ||||
| 1 | Acquired methaemoglobinaemia [ICD-11: 3A93] | |||||
| 2 | Alzheimer disease [ICD-11: 8A20] | |||||
| 3 | Depression [ICD-11: 6A70-6A7Z] | |||||
| 4 | Hypertension [ICD-11: BA00-BA04] | |||||
| 5 | Parkinsonism [ICD-11: 8A00] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 8 Approved Drugs | + | ||||
| 1 | Clorgyline | Drug Info | Approved | Parkinson disease | [2], [3], [4] | |
| 2 | Ergoloid mesylate | Drug Info | Approved | Alzheimer disease | [5] | |
| 3 | Methylene blue | Drug Info | Approved | Acquired methemoglobinemia | [6] | |
| 4 | Moclobemide | Drug Info | Approved | Depression | [7], [8] | |
| 5 | Pargyline | Drug Info | Approved | Hypertension | [4] | |
| 6 | Phenelzine | Drug Info | Approved | Depression | [4], [9], [10] | |
| 7 | Selegiline | Drug Info | Approved | Major depressive disorder | [11], [12] | |
| 8 | Tranylcypromine | Drug Info | Approved | Major depressive disorder | [4] | |
| Patented Agent(s) | [+] 2 Patented Agents | + | ||||
| 1 | (-)-deprenyl | Drug Info | Patented | Alopecia | [13] | |
| 2 | Lazabemide | Drug Info | Patented | Skin imperfections | [13] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 13 Inhibitor drugs | + | ||||
| 1 | Clorgyline | Drug Info | [13] | |||
| 2 | Moclobemide | Drug Info | [13] | |||
| 3 | Pargyline | Drug Info | [13] | |||
| 4 | Phenelzine | Drug Info | [13] | |||
| 5 | Selegiline | Drug Info | [13] | |||
| 6 | Tranylcypromine | Drug Info | [13] | |||
| 7 | (-)-deprenyl | Drug Info | [13] | |||
| 8 | Cyclopropylamine derivative 11 | Drug Info | [15] | |||
| 9 | Cyclopropylamine derivative 12 | Drug Info | [15] | |||
| 10 | Cyclopropylamine derivative 13 | Drug Info | [15] | |||
| 11 | Cyclopropylamine derivative 9 | Drug Info | [15] | |||
| 12 | Lazabemide | Drug Info | [13] | |||
| 13 | PMID27019002-Compound-20a | Drug Info | [15] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Ergoloid mesylate | Drug Info | [1] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6636). | |||||
| REF 3 | Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. | |||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 5 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 081113. | |||||
| REF 6 | Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett. 1998 Feb 6;422(3):311-4. | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7428). | |||||
| REF 8 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
| REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7266). | |||||
| REF 10 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011909. | |||||
| REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6639). | |||||
| REF 12 | ClinicalTrials.gov (NCT00640159) Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. U.S. National Institutes of Health. | |||||
| REF 13 | Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. | |||||
| REF 14 | Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9. | |||||
| REF 15 | LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.